Recursion Pharmaceuticals Inc (RXRX)
5.695
-0.06
(-0.96%)
USD |
NASDAQ |
Nov 22, 16:00
5.75
+0.06
(+0.97%)
After-Hours: 19:04
Recursion Pharmaceuticals Revenue (Quarterly): 26.08M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 26.08M |
| June 30, 2024 | 14.40M |
| March 31, 2024 | 13.49M |
| December 31, 2023 | 10.62M |
| September 30, 2023 | 10.10M |
| June 30, 2023 | 11.02M |
| March 31, 2023 | 12.13M |
| December 31, 2022 | 13.68M |
| September 30, 2022 | 13.05M |
| Date | Value |
|---|---|
| June 30, 2022 | 7.653M |
| March 31, 2022 | 5.299M |
| December 31, 2021 | 2.50M |
| September 30, 2021 | 2.50M |
| June 30, 2021 | 2.50M |
| March 31, 2021 | 2.50M |
| December 31, 2020 | 2.551M |
| September 30, 2020 | 0.862M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.862M
Minimum
Sep 2020
26.08M
Maximum
Sep 2024
8.879M
Average
10.10M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| Revance Therapeutics Inc | 59.88M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -95.84M |
| Total Expenses (Quarterly) | 124.44M |
| EPS Diluted (Quarterly) | -0.34 |
| Enterprise Value | 1.249B |
| Gross Profit Margin (Quarterly) | 53.69% |
| Profit Margin (Quarterly) | -367.5% |
| Earnings Yield | -27.22% |
| Normalized Earnings Yield | -27.22 |